Our four clinical sites ensure Sponsors meet standards of consistency and reliability for POC. And a single point of contact guides your study through the regulatory and contracts processes.

We combine sensitive and reliable efficacy determinations with a unique charting method to systematically capture all observations, including adverse events. We can combine PK sampling, complex circadian based assessments, and frequent sponsor-investigator conference calls to ensure a true partnership in ongoing research. CCT's track record for Phase IB/IIA Proof of Concept Studies also includes the development of compounds for both psychiatric and neurological disorders.

CCT has experience with cutting edge compounds and therapeutic classes including:

• Neuropeptide modulators targeting Substance P and opioid systems
• CRF and Cortisol modulators
• Novel transporter inhibitors for neurotransmitters
• Triptans
• Novel antipsychotic agents with widely varying pharmacological profiles
• A wide array of therapies for Alzheimer's Disease (treatment and disease modification)
• Immunological modifiers for CNS processes

Click here to contact us about your Proof of Concept study.